The Chinese National Medical Products Administration (NMPA) has approved Keytruda (pembrolizumab) as a second-line therapy for patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors have at least 10% of cells producing the PD-L1 protein. With the new approval, Keytruda is now available in China for five indications across three different types of cancer. It can be used as a first-line treatment for advanced non-small cell lung cancer and as a…
You must be logged in to read/download the full post.
The post Keytruda Approved in China as Second-line Therapy for Advanced Esophageal Cancers appeared first on BioNewsFeeds.